[基于BCMA的CAR-T细胞治疗复发性/耐药性多发性骨髓瘤患者的肝脏指数观察]
1Hematology Institute of Xuzhou Medical University, Hematology Department of The Affiliated Hospital of Xuzhou Medical University, Jiangsu Provincial Key Laboratory of Bone Marrow Stem Cells, Xuzhou 221002, China.
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
|December 4, 2023
概括
细胞因子释放综合征 (CRS) 在接受BCMA向的CAR-T细胞治疗的复发性/耐药性多发性骨髓瘤患者的肝功能上有显著影响. 这些肝指数变化通常是短暂的,在适当的治疗下是可逆的.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
更多相关视频
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.7K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
539
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)